Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding

Authors


  • Disclosure none

Vincent M. Figueredo, MD, Albert Einstein Medical Center, 5501 Old York Road, Levy 3232 Philadelphia, PA 19141, USA
Tel.: + 1 215 456 8991
Fax: + 1 215 456 3533
Email: figueredov@einstein.edu

Summary

Statins are a cornerstone in reducing cardiovascular events. Studies show that statins are beneficial even in patients with normal or low cholesterol levels, indicating pleiotropic mechanisms of therapeutic benefit apart from their antihyperlipidemic effect. Non-randomised, observational and retrospective studies suggest that statins are associated with better outcomes in patients with heart failure (HF) of both ischaemic and non-ischaemic aetiologies. While cholesterol reduction and plaque stabilisation likely play a role in reducing cardiovascular events in ischaemic HF patients, the mechanisms underlying the benefit in non-ischaemic HF patients is less clear. This review suggests the pleiotropic effects of statin therapy can beneficially alter the pathophysiological mechanisms underlying the clinical benefit observed in non-ischaemic HF patients.

Ancillary